The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Medical Marketing in the United States, 1997-2016
Abstract
IMPORTANCE: Manufacturers, companies, and health care professionals and organizations use an array of promotional activities to sell and increase market share of their products and services. These activities seek to shape public and clinician beliefs about laboratory testing, the benefits and harms of prescription drugs, and some disease definitions. OBJECTIVE: To review the marketing of prescription drugs, disease awareness campaigns, health services, and laboratory tests and the related consequences and regulation in the United States over a 20-year period (1997-2016). EVIDENCE: Analysis (1997-2016) of consumer advertising (Kantar Media data for spending and number of ads); professional marketing (IQVIA Institute for Human Data Science, Open Payments Data [Centers for Medicare & Medicaid Services]); regulations and legal actions of the US Food and Drug Administration (FDA), Federal Trade Commission (FTC), state attorneys general, and US Department of Justice; and searches (1975-2018) of peer-reviewed medical literature (PubMed), business journals (Business Source Ultimate), and news media (Lexis Nexis) for articles about expenditures, content, and consequences and regulation of consumer and professional medical marketing. Spending is reported in 2016 dollars. FINDINGS: From 1997 through 2016, spending on medical marketing of drugs, disease awareness campaigns, health services, and laboratory testing increased from $17.7 to $29.9 billion. The most rapid increase was in direct-to-consumer (DTC) advertising, which increased from $2.1 billion (11.9%) of total spending in 1997 to $9.6 billion (32.0%) of total spending in 2016. DTC prescription drug advertising increased from $1.3 billion (79 000 ads) to $6 billion (4.6 million ads [including 663 000 TV commercials]), with a shift toward advertising high-cost biologics and cancer immunotherapies. Pharmaceutical companies increased DTC marketing about diseases treated by their drugs with increases in disease awareness campaigns from 44 to 401 and in spending from $177 million to $430 million. DTC advertising for health services increased from $542 million to $2.9 billion, with the largest spending increases by hospitals, dental centers, cancer centers, mental health and addiction clinics, and medical services (eg, home health). DTC spending on advertising for laboratory tests (such as genetic testing) increased from $75.4 million to $82.6 million, although the number of ads increased more substantially (from 14 100 to 255 300), reflecting an increase in less expensive electronic media advertising. Marketing to health care professionals by pharmaceutical companies accounted for most promotional spending and increased from $15.6 billion to $20.3 billion, including $5.6 billion for prescriber detailing, $13.5 billion for free samples, $979 million for direct physician payments (eg, speaking fees, meals) related to specific drugs, and $59 million for disease education. Manufacturers of FDA-approved laboratory tests paid $12.9 million to professionals in 2016. From 1997 through 2016, the number of consumer and professional drug promotional materials that companies submitted for FDA review increased from 34 182 to 97 252, while FDA violation letters for misleading drug marketing decreased from 156 to 11. Since 1997, 103 financial settlements between drug companies and federal and state governments resulted in more than $11 billion in fines for off-label or deceptive marketing practices. The FTC has acted against misleading marketing by a single for-profit cancer center. CONCLUSIONS AND RELEVANCE: Medical marketing increased substantially from 1997 through 2016, especially DTC advertising for prescription drugs and health services. Pharmaceutical marketing to health professionals accounted for most spending and remains high even with new policies to limit industry influence. Despite the increase in marketing over 20 years, regulatory oversight remains limited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Health Care Spending in the United States and Other High-Income Countries
Papanicolas, I., Woskie, L. R., & Jha, A. K. (2018) · JAMA · doi:10.1001/jama.2018.1150 · Cited by 1,626
Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?
Wazana, A. (2000) · JAMA · doi:10.1001/jama.283.3.373 · Cited by 1,415
The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction
Kolodny, A., Courtwright, D. T., Hwang, C. S., Kreiner, P., Eadie, J. L., Clark, T. W., & Alexander, G. C. (2015) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-031914-122957 · Cited by 1,388
U.S. Government Accountability Office
(2013) · Choice Reviews Online · doi:10.5860/choice.50-5961 · Cited by 997
New Technology and Health Care Costs — The Case of Robot-Assisted Surgery
Barbash, G. I., & Glied, S. A. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1006602 · Cited by 993
The Promotion and Marketing of OxyContin: Commercial Triumph, Public Health Tragedy
Van Zee, A. (2009) · American Journal of Public Health · doi:10.2105/ajph.2007.131714 · Cited by 910
Kravitz, R. L., Epstein, R. M., Feldman, M. D., Franz, C. E., Azari, R., Wilkes, M. S., Hinton, L., & Franks, P. (2005) · JAMA · doi:10.1001/jama.293.16.1995 · Cited by 586
Scientific versus commercial sources of influence on the prescribing behavior of physicians
Avorn, J., Chen, M., & Hartley, R. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90911-1 · Cited by 559
Spurling, G. K., Mansfield, P. R., Montgomery, B. D., Lexchin, J., Doust, J., Othman, N., & Vitry, A. I. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000352 · Cited by 526
Gagnon, M.-A., & Lexchin, J. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050001 · Cited by 502
Cited by
Humphreys, K., Shover, C. L., Andrews, C. M., Bohnert, A. S. B., Brandeau, M. L., Caulkins, J. P., Chen, J. H., Cuéllar, M.-F., Hurd, Y. L., Juurlink, D. N., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02252-2 · Cited by 421
Gottlieb, J. F., Benedetti, F., Geoffroy, P. A., Henriksen, T. E. G., Lam, R. W., Murray, G., Phelps, J., Sit, D., Swartz, H. A., Crowe, M., et al. (2019) · Bipolar Disorders · doi:10.1111/bdi.12847 · Cited by 196
Emerging technologies and analytics for a new era of value-centered marketing in healthcare
Agarwal, R., Dugas, M., Gao, G. (., & Kannan, P. K. (2020) · Journal of the Academy of Marketing Science · doi:10.1007/s11747-019-00692-4 · Cited by 175
Chervenak, J., Lieman, H., Blanco-Breindel, M., & Jindal, S. (2023) · Fertility and Sterility · doi:10.1016/j.fertnstert.2023.05.151 · Cited by 87
The Changing Medical Publishing Industry: Economics, Expansion, and Equity
Booth, C. M., Ross, J. S., & Detsky, A. S. (2023) · Journal of General Internal Medicine · doi:10.1007/s11606-023-08307-z · Cited by 27
Metadata
- Authors
- Schwartz, L. M., & Woloshin, S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2019-01-01
- Volume
- 321
- Issue
- 1
- Pages
- 80
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2909660049
- Cited by
- 379
- References
- 53
- FWCI
- 44.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Medical Marketing in the United States, 1997-2016. https://app.cochat.ai/papers/10.1001/jama.2018.19320
- The paper
- Schwartz, L. M., & Woloshin, S. (2019). Medical Marketing in the United States, 1997-2016. JAMA. https://doi.org/10.1001/jama.2018.19320
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.